PharmaShots

JUNE 16, 2023

Date: June 12, 2023 | Tags: Novartis, Chinook Therapeutics, Atrasentan, Zigakibart, BION-1301, IgA nephropathy, M&A, ~$3.5B Date: June 12, 2023 | Tags: Novartis, Chinook Therapeutics, Atrasentan, Zigakibart, BION-1301, IgA nephropathy, M&A, ~$3.5B

FDA 40

FDA Labelling 40

European Pharmaceutical Review

DECEMBER 9, 2022

Tag Copenhagen A/S (Denmark). Microsynth AG (Switzerland). Eurofins Scientific (Germany). Ionis Pharmaceuticals, Inc. (US). LGC Limited (UK). Kaneka Corporation (Japan). Thermo Fisher Scientific, Inc. (US). Twist Bioscience Corporation (US). Maravai Life Sciences (US). Merck KGaA (Germany). Sarepta Therapeutics, Inc. (US).

Compounding 89

Compounding 89

pharmaphorum

NOVEMBER 16, 2021

. “We look forward to the full technology appraisal guidance (TAG) which is due to be published in early December 2021,” he added. An opinion from the Scottish Medicine Consortium (SMC) on the use of the drug by NHS Scotland is expected to be published early in 2022.

Documentation 87

Documentation 87

Pharmaceutical Technology

MARCH 17, 2023

In some cases, she said, “[drug] innovation would have been otherwise hindered by their price tag alone”. Watt explained that for newer, first-in-class drugs these types of agreements can also give healthcare systems safety in their decisions to approve certain drugs. Click here to watch this webinar and access the presentation.

Pharmaceutical Companies 102

Pharmaceutical Companies Pharmaceutical Companies Communication 102

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. Switzerland. Novo Nordisk is another company leading the charge in this field. In a Phase II study, CagriSema achieved a numerically higher body weight reduction of 15.6%

Insurance 105

Insurance Labelling Communication FDA 105

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. Switzerland. Novo Nordisk is another company leading the charge in this field. In a Phase II study, CagriSema achieved a numerically higher body weight reduction of 15.6%

Insurance 98

Insurance Labelling Communication FDA 98